You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Monoclonal Antibody Therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Cancer Trial in New York (Monoclonal antibody hu3S193)

Terminated
Has Results
  • Ovarian Cancer
  • Monoclonal antibody hu3S193
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Colorectal Cancer Trial in New York (mAb hu3S193)

Terminated
Has Results
  • Colorectal Cancer
  • monoclonal antibody hu3S193
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Kidney Cancer Trial in New York (Iodine-131 radiolabeled chimeric mAb G250 (131I-cG250))

Completed
Has Results
  • Kidney Cancer
  • Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Bevacizumab Combined With PD-1 Monoclonal Antibody in

Not yet recruiting
  • Colorectal Cancer
  • Bevacizumab Combined With PD-1 Monoclonal Antibody
  • (no location specified)
Nov 8, 2023

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

Rectal Cancer Trial (Short-course radiotherapy combined with furoquintinib and PD-1 mAb)

Not yet recruiting
  • Rectal Cancer
  • Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody
  • (no location specified)
Aug 29, 2023

MSS, Rectal Cancer Trial (Sintilimab with Interleukin-2)

Not yet recruiting
  • MSS
  • Rectal Cancer
  • Sintilimab with Interleukin-2
  • (no location specified)
Nov 1, 2023

Lymphoma Trial in Stanford (rituximab)

Completed
  • Lymphoma
  • rituximab
  • Stanford, California
    Stanford University Medical Center
May 25, 2022

Lung Cancer Trial in New York (mAb hu3S193)

Completed
Has Results
  • Lung Cancer
  • monoclonal antibody hu3S193
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Feb 7, 2022

Herpes Labialis Trial in Germany (drug, behavioral, procedure)

Active, not recruiting
  • Herpes Labialis
  • HDIT101 (blinded therapy)
  • +5 more
  • Berlin, Germany
  • +4 more
Jan 26, 2023

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 Trial

Recruiting
  • Anatomic Stage I Breast Cancer AJCC v8
  • +19 more
  • pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 1, 2022

NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • 4 cycles of ESA regimen with sandwiched radiotherapy
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 29, 2023

Colorectal Cancer Trial (Serplulimab + FOLFOXIRI, Radiation therapy)

Not yet recruiting
  • Colorectal Cancer
  • Serplulimab + FOLFOXIRI
  • Radiation therapy
  • (no location specified)
Oct 24, 2023

Primary Immune Thrombocytopenia (ITP) Trial in Tianjin (TPO-RAs, TPO-RAs combining anti-CD 20 mAb)

Not yet recruiting
  • Primary Immune Thrombocytopenia (ITP)
  • TPO-RAs
  • TPO-RAs combining anti-CD 20 monoclonal antibody
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital, Chinese Aca
Feb 7, 2023

Colorectal Cancer Metastatic Trial (HLX26, HLX10)

Not yet recruiting
  • Colorectal Cancer Metastatic
  • (no location specified)
Oct 14, 2022

NSCLC Trial in Guangzhou (PEF, Anti-PD-1 mAb)

Recruiting
  • NSCLC
  • PEF
  • Anti-PD-1 monoclonal antibody
  • Guangzhou, Guangdong, China
    The first Affiliated Hospital of Guangzhou Medical University
Aug 3, 2023

Gastric Cancer Trial in Shanghai (NK510, Tislelizumab,atezolizumab or Trastuzumab)

Enrolling by invitation
  • Gastric Cancer
  • NK510
  • Tislelizumab，atezolizumab or Trastuzumab
  • Shanghai, China
    Shanghai Tenth People's Hospital
Oct 22, 2023

Asthma Trial in Shanghai (610 30mg group, 610 100mg group, 610 300mg group)

Active, not recruiting
  • Asthma
  • 610 30mg group
  • +5 more
  • Shanghai, Shanghai, China
    Shanghai General Hospital
Oct 17, 2022

Solid Tumor Trial (IN10018, Nab-paclitaxel, Tislelizumab)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Aug 1, 2023

Recurrent Adult Hodgkin Lymphoma Trial in Duarte (biological, drug, other, procedure)

Active, not recruiting
  • Recurrent Adult Hodgkin Lymphoma
  • basiliximab
  • +8 more
  • Duarte, California
    City of Hope Medical Center
Mar 17, 2022

Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)

Recruiting
  • Nasopharyngeal Carcinoma
  • Anti-EGFR and PD-1 inhibitor arm
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 26, 2023

Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic

Recruiting
  • Pancreatic Ductal Adenocarcinoma, PDAC
    • Shanghai, Shanghai, China
      Ruijin Hospital
    Jan 24, 2022

    Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1

    Active, not recruiting
    • Ann Arbor Stage I Grade 1 Follicular Lymphoma
    • +3 more
    • Clinical Observation
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 5, 2022

    HIV-1-infection Trial in Mbeya (ART, 10E8.4/iMab, VRC07-523LS)

    Not yet recruiting
    • HIV-1-infection
    • Mbeya, Tanzania
      National Institute for Medical Research-Mbeya Medical Resarch Ce
    Jun 6, 2023

    Recurrent Brain Tumor Trial in Houston (biological, other, radiation)

    Active, not recruiting
    • Recurrent Brain Neoplasm
    • Bevacizumab
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 9, 2022